Connect with us

Lifestyle

Letter Written By A 27-Year-Old One Day Before Her Death Really Puts Things Into Perspective

After being diagnosed with a rare form of cancer called Ewig’s sarcoma, Holly came to terms with her mortality and wanted to share her last thoughts with the world.

Published

on

Just a few days ago, a 27-year-old woman named Holly Butcher passed away from a rare form of cancer known as Ewig’s sarcoma, which primarily affects young people. After coming to terms with her mortality, Holly wanted to share what she came to understand about life after being faced with inevitable death.

advertisement - learn more

Holly’s words serve as a powerful reminder to appreciate the life that we are given, focus on what’s really important and have gratitude for the ability to even take a breath. If you knew you were going to die tomorrow, it is very possible that the same things that feel so important to you now may one day not even cross your mind the day before passing away.

Holly’s message has been shared all over the internet and for good reason, perhaps her last words will help to put things into perspective for all of us who unknowingly take our lives for granted.

What is really important to you? This is a great question to ask yourself. Check out Holly’s powerful “life advice” that she wanted to share before passing away.

A bit of life advice from Hol:

It’s a strange thing to realise and accept your mortality at 26 years young. It’s just one of those things you ignore. The days tick by and you just expect they will keep on coming; Until the unexpected happens. I always imagined myself growing old, wrinkled and grey- most likely caused by the beautiful family (lots of kiddies) I planned on building with the love of my life. I want that so bad it hurts…

advertisement - learn more

Posted by Holly Butcher on Wednesday, January 3, 2018

 

Thank you for the beautiful reminder and last words. Holly, may your body rest in peace and your spirit live on forever.

Much Love

Help Support Collective Evolution

The demand for Collective Evolution's content is bigger than ever, except ad agencies and social media keep cutting our revenues. This is making it hard for us to continue.

In order to stay truly independent, we need your help. We are not going to put up paywalls on this website, as we want to get our info out far and wide. For as little as $3 a month, you can help keep CE alive!

SUPPORT CE HERE!

cards

Advertisement
advertisement - learn more

Awareness

Long-Term Consequences of Mumps Vaccination: Many Unanswered Questions

Published

on

This is Part II of a two-part series on mumps. Part I discussed how mumps vaccination and the flawed mumps component of Merck’s MMR vaccine are fostering dangerous mumps outbreaks in adolescents and young adults.

It has been about five decades since the U.S. Food and Drug Administration (FDA) approved Merck’s first mumps vaccine. The company began launching combination MMR (measles, mumps and rubella) vaccines in the 1970s. Coincidentally—or not—an infertility crisis has been brewing over roughly the same time period, with dramatic declines in sperm counts and record-lowfertility levels. However, few investigators seem interested in assessing whether mumps outbreaks in highly vaccinated populations of teens and young adults could be having long-termeffects on fertility or other health indicators.

As described in Part I, childhood MMR vaccination has been an unmitigated disaster where mumps is concerned, deferring mumps infection to older ages and leaving adolescents and young adults vulnerable to serious reproductive complications. Public health reports show that the vast majority of mumps cases and outbreaks occur in youth who have been fully vaccinatedwith the prescribed two-dose MMR series, supporting a hypothesis of “waning immunity after the second dose.” FDA and Centers for Disease Control and Prevention (CDC) officials even admitthat mumps outbreaks in the post-vaccination era “typically involve young adults,” and that vaccination is failing to protect those who are college-age and above.

Myopically, many vaccine experts have called for a third MMR dose—or even “booster dosing throughout adulthood”—even though the FDA’s and CDC’s own research shows that MMR boosters in college-age youth barely last one year. As alleged in whistleblower lawsuits wending their way through the courts over the past eight years, Merck presented the FDA with a “falsely inflated efficacy rate” for the MMR’s mumps component, using animal antibodies and other fraudulent tactics to fool FDA—and the public—into believing that the vaccine was effective.

When infection arises after puberty, however, mumps is no laughing matter, presenting an increased risk of complications such as hearing loss, encephalitis and inflammation of the reproductive organs.

Mumps after puberty is no laughing matter

Around the time that the first mumps vaccine came on the market, the 1967 children’s classic The Great Brain humorously depicted mumps infection in childhood as a mere nuisance. The book’s young protagonist goes out of his way to intentionally infect himself with mumps so that he can beat his two brothers to the recovery finish line—and he experiences no adverse consequences other than his siblings’ annoyance.

advertisement - learn more

When infection arises after puberty, however, mumps is no laughing matter, presenting an increased risk of complications such as hearing loss, encephalitis and inflammation of the reproductive organs. About one in three postpubertal men with mumps develops orchitis(inflammation of the testes), which can damage sperm, affect testosterone production and contribute to subfertility and infertility. During a mumps outbreak in England in the mid-2000s, mumps orchitis accounted for 42% of all hospitalized mumps cases; the researchers attributed this outcome—which was the most common reason for hospitalization—to “the high attack rates in adolescents and young adults” that occurred “despite high coverage with two-dose MMR.” An analysis of a 2006 mumps outbreak in the U.S. reported that male patients were over three times more likely than female patients to experience complications, “due primarily to orchitis.”

An estimated 5% to 10% of postpubertal women will develop oophoritis (swelling of the ovaries) following mumps infection. Oophoritis is associated with premature menopause and infertility, but mumps-related oophoritis has garnered little notice.

Mumps infections are often asymptomatic or produce nonspecific symptoms such as fever, while cases of orchitis may present with no other mumps symptoms. Nonetheless, public health officials advise clinicians that orchitis is an instant cue to test for mumps virus, and testing often reveals elevated mumps antibodies. In a case report of MMR failure, British clinicians isolated a novel genetic strain of mumps virus from the patient’s semen two weeks after the onset of orchitis and found mumps RNA in the semen 40 days later; they also noted “the appearance of anti-sperm antibodies,” with “potential long-term adverse effects on the patient’s fertility.”

In 2017, researchers who reviewed 185 studies conducted in Western nations found that sperm counts had plummeted by 50% to 60% between 1973 and 2011—an average decrease of 1.4% annually. Commenting on this work, one analyst estimated that 20% to 30% of young men in Europe and North America have sperm concentrations associated with a reduced ability to father a child. Given estimates that as much as 40% of reproductive problems have to do with the male partner, there is agreement on the importance of “finding and eliminating [the] hidden culprits in the environment” that most researchers believe are to blame.

An estimated 5% to 10% of postpubertal women will develop oophoritis (swelling of the ovaries) following mumps infection. Oophoritis is associated with premature menopause and infertility, but mumps-related oophoritis has garnered little notice.

MMR’s and MMRV’s potential to impair fertility never studied

Merck has not evaluated either of its two MMR vaccines—the MMR-II and the MMR-plus-varicella (MMRV) vaccine—for their potential to impair fertility. Whether such testing would unearth direct effects on fertility (as appears to be possible with HPV vaccination in women) is thus unknown. However, mumps vaccination undeniably increases reproductive-age individuals’ risk of mumps infection and, in the process, increases the risk of fertility-altering complications. These facts alone should be attracting far more attention.

Unfortunately, because clinicians already tend to underdiagnose mumps infection and underestimate mumps complications, it is likely that they are failing to recognize possible vaccine-induced reproductive health consequences of mumps infection in their adolescent and young adult patients. In one university outbreak, “most physicians…did not suspect mumps,” and even when they became aware of the outbreak, “diagnosing mumps was not always straightforward.” Moreover, although differentiating between vaccine strains of mumps virus and wild types could provide valuable information, few clinicians have the capacity or inclination to perform testing of this type. A Japanese study of cerebrospinal fluid and saliva from patients with mumps complications found vaccine strain in nearly all of the samples and noted the information’s importance in helping determine whether the complications were vaccine-related.

Those who have sought to understand mumps vaccines’ poor performance point to a mixture of explanatory factors. These include waning immunity, the high population density and close quarters encountered in settings such as college campuses, incomplete vaccine-induced immunity to wild virus as well as viral evolution such that “the vaccine triggers a less potent reaction against today’s mumps viruses than those of 50 years ago.” However, some also quietly admit that individuals with “mild vaccine-modified disease” could be perpetuating the chain of transmission. This latter point ought to be raising questions about the logic and wisdom of administering further rounds of MMR boosters during outbreaks while ignoring the problems created by the doses already given.

… some individuals respond poorly to mumps vaccination and vaccine-induced antibody levels correlate poorly with protection from mumps infection, irrespective of the number of additional doses of mumps-containing vaccine they receive.

Most scientists appear to be either resigned to ongoing mumps outbreaks in vaccinated populations or actually accept periodic outbreaks as the cost of doing business. Publications by FDA and CDC researchers reveal these agencies’ awareness that some individuals respond poorly to mumps vaccination and that vaccine-induced antibody levels correlate poorly with protection from mumps infection, “irrespective of the number of additional doses of mumps-containing vaccine they receive.” Considering the effects on fertility, the generally abysmal track record of mumps vaccination and Merck’s fraudulent claims about efficacy, it is hard to fathom medical and public health experts’ complacency about current mumps vaccines and vaccine policies.


Sign up for free news and updates from Robert F. Kennedy, Jr. and the Children’s Health Defense. CHD is planning many strategies, including legal, in an effort to defend the health of our children and obtain justice for those already injured. Your support is essential to CHD’s successful mission.

Help Support Collective Evolution

The demand for Collective Evolution's content is bigger than ever, except ad agencies and social media keep cutting our revenues. This is making it hard for us to continue.

In order to stay truly independent, we need your help. We are not going to put up paywalls on this website, as we want to get our info out far and wide. For as little as $3 a month, you can help keep CE alive!

SUPPORT CE HERE!

cards

Continue Reading

Awareness

Magnesium Puts Psychiatric Drugs to Shame for Depression

Published

on

In Brief

  • The Facts:

    This article was written by Sayer Ji, Founder of Greenmedinfo.com where this article first appeared. Posted here with permission.

  • Reflect On:

    Is the priority of our federal health regulatory agencies and pharmaceutical companies human health, or profit? If there are more effective ways to treat several illnesses, why do they never mention them?

Depression is one of the most widely diagnosed conditions of our time, with over 3 million cases in the U.S. every year, and 350 million believed affected worldwide.1 Conventional medicine considers antidepressant drugs first-line treatments, including the newly approved injected postpartum drug costing $34,000 a treatment, to the tune of a 16 billion dollars in global sales by 2023. Despite their widespread use, these drugs are fraught with a battery of serious side effects, including suicidal ideation and completion — the last two things you would hope to see in a condition that already has suicidality as a co-morbidity. For this reason alone, natural, safe, and effective alternatives are needed more than ever before.

While research into natural alternatives for depression is growing daily — GreenMedInfo.com’s Depression database contains 647 studies on over 100 natural substances that have been studied to prevent or treat depression — it is rare to find quality human clinical research on the topic published in well-respected journals. That’s why a powerful study published in PLOS One titled, “Role of magnesium supplementation in the treatment of depression: A randomized clinical trial,” is so promising. Not only is magnesium safe, affordable, and easily accessible, but according to this recent study, effective in treating mild-to moderate symptoms of depression.

While previous studies have looked at the association between magnesium and depression,2-7 this is the first placebo-controlled clinical study to evaluate whether the use of over-the-counter magnesium chloride (248 mg elemental magnesium a day for 6 weeks) improves symptoms of depression.

The study design was a follows:

“ An open-label, blocked, randomized, cross-over trial was carried out in outpatient primary care clinics on 126 adults (mean age 52; 38% male) diagnosed with and currently experiencing mild-to-moderate symptoms with Patient Health Questionnaire-9 (PHQ-9) scores of 5–19. The intervention was 6 weeks of active treatment (248 mg of elemental magnesium per day) compared to 6 weeks of control (no treatment). Assessments of depression symptoms were completed at bi-weekly phone calls. The primary outcome was the net difference in the change in depression symptoms from baseline to the end of each treatment period. Secondary outcomes included changes in anxiety symptoms as well as adherence to the supplement regimen, appearance of adverse effects, and intention to use magnesium supplements in the future. Between June 2015 and May 2016, 112 participants provided analyzable data.”

The study results were as follows:

advertisement - learn more

“Consumption of magnesium chloride for 6 weeks resulted in a clinically significant net improvement in PHQ-9 scores of -6.0 points (CI -7.9, -4.2; P<0.001) and net improvement in Generalized Anxiety Disorders-7 scores of -4.5 points (CI -6.6, -2.4; P<0.001). Average adherence was 83% by pill count. The supplements were well tolerated and 61% of participants reported they would use magnesium in the future. Similar effects were observed regardless of age, gender, baseline severity of depression, baseline magnesium level, or use of antidepressant treatments. Effects were observed within two weeks. Magnesium is effective for mild-to-moderate depression in adults. It works quickly and is well tolerated without the need for close monitoring for toxicity.”

 For perspective, conventional antidepressant drugs are considering to generate an “adequate or complete treatment response” with a PHQ-9 score “decrease of 5 points or more from baseline.” At this level of efficacy, their recommended action is: “Do not change treatment; conduct periodic follow-up.” The magnesium’s score of -6.0 therefore represents the height of success within conventional expectations for a complete response, which is sometimes termed “remission.” In contradistinction, conventional antidepressant drugs result in nearly half of patients discontinuing treatment during the first month, usually due to their powerful and sometimes debilitating side effects.8

To summarize the main study outcomes:

  • There was a clinically significant improvement in both Depression and Anxiety scores.
  • 61% of patients reported they would use magnesium in the future.
  • Similar effects occurred across age, gender, severity of depression, baseline magnesium levels, or use of antidepressant treatments.
  • Effects were observed within two weeks.

 The study authors concluded:

“Magnesium is effective for mild-to-moderate depression in adults. It works quickly and is well tolerated without the need for close monitoring for toxicity.”

Beyond Depression: Magnesium’s Many Health Benefits & Where To Source It

Magnesium is a central player in your body’s energy production, as its found within 300 enzymes in the human body, including within the biologically active form of ATP known as MG-ATP. In fact, there have been over 3,751 magnesium binding sites identified within human proteins, indicating that it’s central nutritional importance has been greatly underappreciated.

Research relevant to magnesium has been accumulating for the past 40 years at a steady rate of approximately 2,000 new studies a year. Our database project has indexed well over 100 health benefits of magnesium thus far.  For the sake of brevity, we will address seven key therapeutic applications for magnesium as follows:

  • Fibromyalgia: Not only is magnesium deficiency common in those diagnosed with fibromyalgia, 9,10 but relatively low doses of magnesium (50 mg), combined with malic acid in the form of magnesium malate, has been clinically demonstrated to improve pain and tenderness in those to which it was administered.11
  • Atrial Fibrillation: A number of studies now exist showing that magnesium supplementation reduce atrial fibrillation, either by itself, or in combination with conventional drug agents.12
  • Diabetes, Type 2: Magnesium deficiency is common in type 2 diabetics, at an incidence of 13.5 to 47.7% according to a 2007 study. 13 Research has also shown that type 2 diabetics with peripheral neuropathy and coronary artery disease have lower intracellular magnesium levels. 14 Oral magnesium supplementation has been shown to reduce plasma fasting glucose and raising HDL cholesterol in patients with type 2 diabetes.15 It has also been shown to improve insulin sensitivity and metabolic control in type 2 diabetic subjects.16
  • Premenstrual Syndrome: Magnesium deficiency has been observed in women affected by premenstrual syndrome.17 It is no surprise therefore  that it has been found to alleviate premenstrual symptoms of fluid retention, 18 as well as broadly reducing associated symptoms by approximately 34% in women, aged 18-45, given 250 mg tablets for a 3-month observational period.20 When combined with B6, magnesium supplementation has been found to improve anxiety-related premenstrual symptoms.19
  • Cardiovascular Disease and Mortality: Low serum magnesium concentrations predict cardiovascular and all-cause mortality.21 There are a wide range of ways that magnesium may confer its protective effects. It may act like a calcium channel blocker,22it is hypotensive,23 it is antispasmodic (which may protect against coronary artery spasm),24 and anti-thrombotic.25 Also, the heart muscle cells are exceedingly dense in mitochondria (as high as 100 times more per cell than skeletal muscle), the “powerhouses” of the cell,” which require adequate magnesium to produce ATP via the citric acid cycle.
  • Migraine Disorders: Blood magnesium levels have been found to be significantly lower in those who suffer from migraine attacks.26,27 A recent Journal of Neural Transmission article titled, “Why all migraine patients should be treated with magnesium,” pointed out that routine blood tests do not accurately convey the true body magnesium stores since less than 2% is in the measurable, extracellular space, “67% is in the bone and 31% is located intracellularly.”28The authors argued that since “routine blood tests are not indicative of magnesium status, empiric treatment with at least oral magnesium is warranted in all migraine sufferers.” Indeed, oral magnesium supplementation has been found to reduce the number of headache days in children experiencing frequent migranous headaches,29and when combined with l-carnitine, is effective at reducing migraine frequency in adults, as well.30
  • Aging: While natural aging is a healthy process, accelerated aging has been noted to be a feature of magnesium deficiency,31especially evident in the context of long space-flight missions where low magnesium levels are associated with cardiovascular aging over 10 times faster than occurs on earth.32 Magnesium supplementation has been shown to reverse age-related neuroendocrine and sleep EEG changes in humans.33 One of the possible mechanisms behind magnesium deficiency associated aging is that magnesium is needed to stabilize DNA and promotes DNA replication. It is also involved in healing up of the ends of the chromosomes after they are divided in mitosis.34

 It is quite amazing to consider the afformentioned side benefits of magnesium consumption or supplementation within the context of the well-known side effects of pharmaceutical approaches to symptom

management of disease. On average, conventional drugs have 75 side effects associated with their use, including lethal ones (albeit sometimes rare). When considering magnesium’s many side benefits

and extremely low toxicity, clearly this fundamental mineral intervention (and dietary requirement) puts pharmaceutical approaches to depression to shame.

Best Sources of Magnesium In The Diet

The best source of magnesium is from food, and one way to identify magnesium-containing foods are those which are green, i.e. chlorophyll rich. Chlorophyll, which enable plants to capture solar energy and convert it into metabolic energy, has a magnesium atom at its center. Without magnesium, in fact, plants could not utilize the sun’s light energy.

Magnesium, however, in its elemental form is colorless, and many foods that are not green contain it as well. The point is that when found complexed with food cofactors, it is absorbed and utilized more efficiently than in its elemental form, say, extracted from limestone in the form of magnesium oxide.

 The following foods contain exceptionally high amounts of magnesium. The portions described are 100 grams, or a little over three ounces.

  • Rice bran, crude (781 mg)
  • Seaweed, agar, dried (770 mg)
  • Chives, freeze-dried (640 mg)
  • Spice, coriander leaf, dried (694 mg)
  • Seeds, pumpkin, dried (535 mg)
  • Cocoa, dry powder, unsweetened (499 mg)
  • Spices, basil, dried (422 mg)
  • Seeds, flaxseed (392 mg)
  • Spices, cumin seed (366 mg)
  • Nuts, brazilnuts, dried (376 mg)
  • Parsley, freeze-dried (372 mg)
  • Seeds, sesame meal (346 mg)
  • Nut, almond butter (303 mg)
  • Nuts, cashew nuts, roasted (273 mg)
  • Soy flour, defatted (290 mg)
  • Whey, sweet, dried (176 mg)
  • Bananas, dehydrated (108 mg)
  • Millet, puffed (106 mg)
  • Shallots, freeze-dried (104 mg)
  • Leeks, freeze-dried (156 mg)
  • Fish, salmon, raw (95 mg)
  • Onions, dehydrated flakes (92 mg)
  • Kale, scotch, raw (88 mg)

 Fortunately, for those who need higher doses, or are not inclined to consume magnesium rich foods, there are supplemental forms commonly available on the market. Keep in mind, for those who wish to take advantage of the side benefit of magnesium therapy, namely, its stool softening and laxative properties, magnesium citrate or oxide will provide this additional feature.

For those looking to maximize absorption and bioavailability magnesium glycinate is ideal, as glycine is the smallest amino acid commonly found chelated to magnesium, and therefore highly absorbable.

For more information on natural solutions to resolving depression, download our free e-book on the topic “21st Century Solutions to Depression.” 

References:

1) World Health Organization. Depression fact sheet no. 369 2012 [cited 2016 December 20]. Available from: http://www.who.int/mediacentre/factsheets/fs369/en/.

2) Jacka FN, Overland S, Stewart R, Tell GS, Bjelland I, Mykletun A. Association between magnesium intake and depression and anxiety in community-dwelling adults: the Hordaland Health Study. Aust N Z J Psychiatry. 2009;43(1):45–52. Pmid:19085527.

3) Huang JH, Lu YF, Cheng FC, Lee JN, Tsai LC. Correlation of magnesium intake with metabolic parameters, depression and physical activity in elderly type 2 diabetes patients: a cross-sectional study. Nutrition J. 2012;11(1):41. pmid:22695027; PubMed Central PMCID: PMC3439347.

4) Tarleton EK, Littenberg B. Magnesium intake and depression in adults. J Am Board Fam Med. 2015;28(2):249–56. Pmid:25748766

5) Yary T, Lehto SM, Tolmunen T, Tuomainen T-P, Kauhanen J, Voutilainen S, et al. Dietary magnesium intake and the incidence of depression: a 20-year follow-up study. J Affect Disord. 2016;193:94–8. Pmid:26771950

6) Eby GA, Eby KL. Rapid recovery from major depression using magnesium treatment. Med Hypotheses. 2006;67(2):362–70. pmid:16542786

7) N Engl J Med. 2000 Dec 28;343(26):1942-50. Managing depression in medical outpatients.

8)  Damiano Piovesan, Giuseppe Profiti, Pier Luigi Martelli, Rita Casadio. 3,751 magnesium binding sites have been detected on human proteins. BMC Bioinformatics. 2012 ;13 Suppl 14:S10. Epub 2012 Sep 7. PMID: 23095498

9) G Moorkens, B Manuel y Keenoy, J Vertommen, S Meludu, M Noe, I De Leeuw. Magnesium deficit in a sample of the Belgian population presenting with chronic fatigue. Magnes Res. 1997 Dec;10(4):329-37. PMID: 9513929

10)  J Eisinger, A Plantamura, P A Marie, T Ayavou. Selenium and magnesium status in fibromyalgia. Magnes Res. 1994 Dec;7(3-4):285-8. PMID: 7786692

11)  I J Russell, J E Michalek, J D Flechas, G E Abraham. Treatment of fibromyalgia syndrome with Super Malic: a randomized, double blind, placebo controlled, crossover pilot study. J Rheumatol. 1995 May;22(5):953-8. PMID: 8587088

12) GreenMedInfo.com, Atrial Fibrillation and Magnesium (5 studies)

13)  Phuong-Chi T Pham, Phuong-Mai T Pham, Son V Pham, Jeffrey M Miller, Phuong-Thu T Pham . Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2007 Mar;2(2):366-73. Epub 2007 Jan 3. PMID: 17699436

14)  M de Lordes Lima, T Cruz, J C Pousada, L E Rodrigues, K Barbosa, V Canguçu. The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes. Diabetes Care. 1998 May;21(5):682-6. PMID: 9589224

15) Y Song, K He, E B Levitan, J E Manson, S Liu. Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes: a meta-analysis of randomized double-blind controlled trials. Cardiovasc Toxicol. 2008;8(3):115-25. Epub 2008 Jul 8. PMID: 16978367

16)  Martha Rodríguez-Morán, Fernando Guerrero-Romero. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care. 2003 Apr;26(4):1147-52. PMID: 12663588

17)  F Facchinetti, P Borella, G Sances, L Fioroni, R E Nappi, A R Genazzani. Oral magnesium successfully relieves premenstrual mood changes. Obstet Gynecol. 1991 Aug;78(2):177-81. PMID: 2067759

18)  A F Walker, M C De Souza, M F Vickers, S Abeyasekera, M L Collins, L A Trinca. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. J Womens Health. 1998 Nov;7(9):1157-65. PMID: 9861593

19)  S Quaranta, M A Buscaglia, M G Meroni, E Colombo, S Cella. Pilot study of the efficacy and safety of a modified-release magnesium 250 mg tablet (Sincromag) for the treatment of premenstrual syndrome. Am J Gastroenterol. 2008 Dec;103(12):2972-6. PMID: 17177579

20) M C De Souza, A F Walker, P A Robinson, K Bolland. A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related premenstrual symptoms: a randomized, double-blind, crossover study. J Womens Health Gend Based Med. 2000 Mar;9(2):131-9. PMID: 10746516

21) Thorsten Reffelmann, Till Ittermann, Marcus Dörr, Henry Völzke, Markus Reinthaler, Astrid Petersmann, Stephan B Felix. Low serum magnesium concentrations predict cardiovascular and all-cause mortality. Atherosclerosis. 2011 Jun 12. Epub 2011 Jun 12. PMID: 21703623

22) Andrea Rosanoff, Mildred S Seelig. Comparison of mechanism and functional effects of magnesium and statin pharmaceuticals. J Am Coll Nutr. 2004 Oct;23(5):501S-505S. PMID: 15466951

23)  GreenMedInfo.com, Magnesium’s Hypotensive Properties.

24) GreenMedInfo.com, Magnesium’s Antispasmodic Properties.

25) Joen R Sheu, George Hsiao, Ming Y Shen, Yen M Lee, Mao H Yen . Antithrombotic effects of magnesium sulfate in in vivo experiments. Int J Hematol. 2003 May;77(4):414-9. PMID: 12774935

26) Afshin Samaie, Nabiollah Asghari, Raheb Ghorbani, Jafar Arda. Blood Magnesium levels in migraineurs within and between the headache attacks: a case control study. Pan Afr Med J. 2012 ;11:46. Epub 2012 Mar 15. PMID: 22593782

27) Mahnaz Talebi, Dariush Savadi-Oskouei, Mehdi Farhoudi, Solmaz Mohammadzade, Seyyedjamal Ghaemmaghamihezaveh, Akbar Hasani, Amir Hamdi. Relation between serum magnesium level and migraine attacks. Neurosciences (Riyadh). 2011 Oct ;16(4):320-3. PMID: 21983373

28) Alexander Mauskop, Jasmine Varughese. Why all migraine patients should be treated with magnesium. J Neural Transm. 2012 May ;119(5):575-9. Epub 2012 Mar 18. PMID: 22426836

29)  Fong Wang, Stephen K Van Den Eeden, Lynn M Ackerson, Susan E Salk, Robyn H Reince, Ronald J Elin. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Eur J Endocrinol. 2009 Apr;160(4):611-7. Epub 2009 Jan 29. PMID: 12786918

30) Ali Tarighat Esfanjani, Reza Mahdavi, Mehrangiz Ebrahimi Mameghani, Mahnaz Talebi, Zeinab Nikniaz, Abdolrasool Safaiyan. The effects of magnesium, L-carnitine, and concurrent magnesium-L-carnitine supplementation in migraine prophylaxis. Biol Trace Elem Res. 2012 Dec ;150(1-3):42-8. Epub 2012 Aug 17. PMID: 22895810

31) David W Killilea, Jeanette A M Maier. A connection between magnesium deficiency and aging: new insights from cellular studies. Magnes Res. 2008 Jun;21(2):77-82. PMID: 18705534

32) GreenMedInfo.com, What We Learned From The Accelerated Aging of Astronauts

33) Katja Held, I A Antonijevic, H Künzel, M Uhr, T C Wetter, I C Golly, A Steiger, H Murck. Oral Mg(2+) supplementation reverses age-related neuroendocrine and sleep EEG changes in humans. Pharmacopsychiatry. 2002 Jul;35(4):135-43. PMID: 12163983

34) William J Rowe. Correcting magnesium deficiencies may prolong life. Clin Interv Aging. 2012 ;7:51-4. Epub 2012 Feb 16. PMID: 22379366


Sayer Ji is founder of Greenmedinfo.com, a reviewer at the International Journal of Human Nutrition and Functional Medicine, Co-founder and CEO of Systome Biomed, Vice Chairman of the Board of the National Health Federation, Steering Committee Member of the Global Non-GMO Foundation.


For more info from Greenmedinfo, you can join their newsletter by clicking here.


Link to original article. 

Help Support Collective Evolution

The demand for Collective Evolution's content is bigger than ever, except ad agencies and social media keep cutting our revenues. This is making it hard for us to continue.

In order to stay truly independent, we need your help. We are not going to put up paywalls on this website, as we want to get our info out far and wide. For as little as $3 a month, you can help keep CE alive!

SUPPORT CE HERE!

cards

Continue Reading

Alternative News

The Fox Owns the Henhouse—When Public Safety is Governed by Private Profit

Published

on

In Brief

  • The Facts:

    This article was written by By José Solís, Ph.D. Posted here with permission.

  • Reflect On:

    Do our federal health regulatory agencies and pharmaceutical companies really put health before profit? Judging by the evidence, profit comes first.

 

“There is more than one way to burn a book. And the world is full of people running about with lit matches.”

― Ray Bradbury, author of Fahrenheit 451

A couple of days ago I stumbled upon a radio interview where the topic was safety and government oversight. I had tuned in at the exact moment when the interviewee said the following:

Well, my experience of 30 years in Washington, D.C. is the same Ronald Reagan had – you know, trust but verify. And when bad things happen, you need to verify if what he is saying is correct. I certainly question that there’s not a cozy relationship. All anyone has to do is look at the revolving door in Washington, D.C., and this agency and the industry to realize that there is a cozy relationship. Now the question is, is that cozy relationship having an adverse impact on the safety decisions being made?

The American public would be surprised, and maybe even concerned, if they knew how widespread the practice of self-regulation was.

advertisement - learn more

Before I could ascertain what they were discussing in the interview, my mind began to race. Could it be clean water, Round Up pesticide lawsuits, climate change, vaccine safety, the opioid crisis? My question was quickly answered. The forum was an interview on National Public Radio(NPR) with former National Transportation Safety Board (NTSB) chairman, James Hall, on the investigation into the recent tragedy of two Boeing 737 MAX airline crashes.  Upon a rewind of the interview, I kept hearing references to “revolving doors” and “cozy relationships.”

David Greene, host of the show, asked,

But are you saying there are documents that Boeing has showing that they’re – that the company and, potentially the FAA, knew that there were some problems, some of the very problems that may have caused these accidents, and that they certified the aircraft anyway?

Mr. Hall responded,

…the process that we presently have is a self-certification process by the manufacturer of the safety of the aircraft… what has happened is that these decisions have been made in commissions and rulemakings dominated by the industry in Washington, D.C.

As reported by NPR, the Federal Aviation Administration (FAA) left the safety testing of the plane to the manufacturing company (Boeing) and that this practice could be found “a lot” in the federal government. James Goodwin of the Center for Progressive Reform stated, “The American public would be surprised, and maybe even concerned, if they knew how widespread the practice of self-regulation was.” I wondered what implications this example might carry for aviation safety, agriculture, vaccine safety, and generally for the future of government oversight and scientific inquiry.

Toward the end of the interview, Mr. Greene from NPR stated that recently he had asked FAA head, Dan Elwell, some of the same questions. In one answer, Mr. Elwell responded, “the FAA is an agency that is based on data, and they very much make their decisions, including keeping those planes in the air, based on data.” Dan Elwell, is a former Vice President of the Aerospace Industries Association, representing the most powerful aerospace industry companies. There remain some very tough questions to be answered by the manufacturers of the airline industry, like Boeing, and the “cozy relationship” it and other industry members enjoy with the government agencies responsible for regulating its operations and overseeing its compliance with public safety. But, let’s move on from that thread of public air safety and pause for an overview of the opioid crisis facing the United States.

Public air safety to the opioid crisis

Earlier in March, the 13th to be precise, I saved a copy of the transcript from an interview between David Greene and Brian Mann, an NPR associate, who has been following developments in some of the lawsuits around the nation’s opioid crisis. In its introduction to the interview NPR reported,

The opioid epidemic claimed 70,000 lives in 2017. To put that in perspective, that is more than the number of people who died annually at the height of the HIV/AIDS epidemic. And the pharmaceutical industry is going to spend much of this year answering some hard questions. Many blame pharma for our country’s opioid crisis. And this year, big drug makers, as well as pharmacy chains, are facing more than 1,500 lawsuits filed by state and local governments. Billions of dollars are at stake, and so are reputations. Johnson & Johnson, Purdue Pharma, CVS – those are just some of the companies targeted in these lawsuits.

The following are excerpts from the interview:

Greene: I mean that there are internal company documents that are being made public, and some of them have been controversial, you’ve been finding.

Mann: Purdue executives, for example, can be seen secretly acknowledging that their prescription opioids were far more addictive and dangerous than they were telling doctors. At the same time, company directives kept pushing sales, pushing the salespeople incredibly hard to get more opioids into the hands of vulnerable people, including seniors and military veterans….We’ve also learned that Purdue Pharma executives developed a secret plan they called Project Tango, which they allegedly hoped might help them profit again from the growing wave of opioid addiction. The idea here was to sell addiction treatment services to some of the same people addicted to products like their own OxyContin… Which means for more than a decade, no one in the wider public knew how serious the allegations against Purdue and these other drug companies were. But this time, states and cities suing these companies seem eager to sort of pull back the curtain… the drug industry has fought these disclosures at every turn. They describe the information in these documents as proprietary, basically arguing its corporate property. But as more and more information comes out, it’s making people angry.

On a related topic, Mr. Mann expressed:

But according to the drug company’s own documents, firms including Johnson & Johnson pushed unscientific theories about drug addiction. They did so allegedly to convince doctors to prescribe even more opioids after patients showed signs of dependency. David Armstrong, the reporter with ProPublica, says this kind of disclosure is making it harder for the industry to protect its image.

… ‘tobacco science;’ i.e. Science done on behalf of an interest defending its profits, like the science conducted by a cigarette company showing that cigarettes are safe.

Government agency collusion

Government agency collusion with different industries, to me, represented nothing short of corruption. I was reminded of the tobacco industry and how the Phillip Morris tobacco company organized its Boca Raton Action Plan in 1988, in an effort to “diffuse and re-orient” the voices and initiatives of those fighting tobacco in favor of public health. Also, how the World Health Organization (WHO) itself colluded with legal experts and doctors in the United States in favor of the tobacco industry and against public health. From this fiasco was coined the expression “tobacco science;” i.e. “Science” done on behalf of an interest defending its profits, like the science conducted by a cigarette company showing that cigarettes are safe.

And speaking of the WHO, I was also reminded of the 2009 H1N1 (swine flu) “pandemic.” In the spring of 2010, the Council of Europe was investigating the role of the WHO in declaring the H1N1 pandemic. Dr. Wolfgang Wodarg, an epidemiologist who at one time was head of the Health Committee of the Council of Europe, expressed concerns that the contracts for the vaccine were mostly confidential arrangements between the WHO, individual member states and the companies producing the vaccine. In fact, numerous countries, including Germany, France, Italy and Great Britain, entered into contracts with the vaccine manufacturing companies prior to the WHO’s declaration of an H1N1 pandemic. The contracts obligated these countries to purchase swine flu vaccinations under one condition: that the WHO issue a pandemic flu alert.

…undermined by the transformation of the relationship between scientists at universities, private industries with their scientists and the ‘cozy relationships’ that exist between the two

Transformed relationships

In his farewell speech to the citizenry, U. S. President Dwight D. Eisenhower poignantly expressed his concern regarding the future of science and its partnership with government, and government with industry, when he said:

…the free university, historically the fountainhead of free ideas and scientific discovery, has experienced a revolution in the conduct of research…The prospect of domination of the nation’s scholars by federal employment, project allocations, and the power of money is ever present and is gravely to be regarded. Yet, in holding scientific research and discovery in respect, as we should, we must also be alert to the equal and opposite danger that public policy could itself become the captive of a scientific-technological elite.

I kept wondering about the revolving doors, the collusion, industrial interests, and the science that was supposed to provide a foundation upon which to rest our confidence, our trust. How did we get here? The short answer, and quite possibly the simplest, might be the privatization of knowledge, or as some have called it, the “selling of science.” Or, maybe it’s the troubled matrimony of science and technology, where an applied and economic gain becomes the foundational rationale for present and future scientific endeavor. Such an environment raises serious questions as to the future of knowledge, the advancement of the sciences, and potential impacts on our economic, social, and public health.

Aristotle reminded us that “knowledge is virtue.” It has a value unto itself; a purpose that serves no particular master other than the rational development of inquiry and respective methods for the development of that knowledge. Here resided the principles of the classic universities, places where questions were explored, answered, and questioned again. This was the meaning of science – never settled – but forever moving toward a better, safer, healthier, and more advanced state of human affairs. But what happens to science when the scientist is tied to private industry, where the principle objective of private industry is defined by its stockholders interests, investments, and profits, where the same industry that manufactures the product for profit is also the industry responsible for generating the science determining the efficacy, effectiveness, and safety of its product?

In his book, Science in the Private Interest, Dr. Sheldon Krimsky writes,

The responsibility of the scientist begins with discovery and ends with commercial applications. Universities exist mainly to provide labor for industry and to help industry turn knowledge into technology; technology into productivity; and productivity into profits.

What Dr. Krimsky refers to as “public interest science as a model of knowledge for human welfare,” has been redefined, or more crudely speaking, undermined by the transformation of the relationship between scientists at universities, private industries with their scientists, and the “cozy relationships” that exist between the two. In the book To Profit or Not To Profit, authors Walter Powell and Jason Owens-Smith state,

The changes underway at universities are the result of multiple forces: a transformation in of the nature policymakers and key constituents. These trends are so potent that there is little chance for reversing them-nor necessarily a rationale for doing so.

These changes have been referred to as characteristic of the scientist as entrepreneur, or parts of what Sheila Slaughter and Larry Leslie explore in their book Academic Capitalism. In it, they write:

We would expect that faculty as professionals participating in academic capitalism would begin to move away from values such as altruism and public service, toward market values.

Under he current science-to-market model, government oversight of any number of products, from airplanes, to drugs, to tobacco, and more, continues to demonstrate a complacency that favors market-driven profits over public safety.

The transformation of science and scientists

The transformation of science and scientists that are lured into and seek financial support from private industry for any number of research-to-market projects has become an all too familiar scenario with potentially devastating consequences.

Most recently, the parents of one of the victims of the Egyptian Boeing airline, filed suit against Boeing and the Rosemont airline parts manufacturing industry. Reuters report states that:

Thursday’s complaint accuses Boeing of putting “profits over safety” and said the U.S. Federal Aviation Administration must also be held accountable for certifying the 737 MAX.

However, reports Reuters: “Legal experts say these cases face high hurdles since government officials and agencies are generally immune from civil lawsuits.”

Under the current science-to-market model, government oversight of any number of products, from airplanes, to drugs, to tobacco, and more, continues to demonstrate a complacency that favors market-driven profits over public safety. This reality should alarm anyone and all. What if, as some of the legal experts above claim, a U.S. citizen has no right to hold industry responsible for assurances of safety because those industries are tied to government agencies, or because those agencies derive profits or “benefits” from the “cozy relationships?” If you believe that the FAA and the FDA need to come clean regarding the “revolving door” and “cozy relationships” that experts have indicated exist between both agencies and private industry, why would we not consider the same for the Centers for Disease Control and Prevention (CDC)?

Arguably, a profoundly vivid parallel is seen in the policies and practices of mandatory vaccination and informed consent. Over the many years studying vaccination theory and practice, I discovered a disturbing similar pattern – the “revolving door” between the CDC and private pharmaceutical manufacturing companies, the conflicts of interest where different committees and their members are given waivers protecting conflicts of interest, payoffs to doctors for administering vaccines, fast-tracking of vaccines and safety studies with no use of double-blind placebo studies, and the very “cozy relationship” between members of Congress, “big pharma,” the CDC and the Food and Drug Administration (FDA).

If you believe that the FAA and the FDA need to come clean regarding the “revolving door” and “cozy relationships” that experts have indicated exists between both agencies and private industry, why would we not consider the same for the Centers for Disease Control and Prevention (CDC)?

In 1986, Congress passed the National Childhood Vaccine Injury Act (NCVIA). For years families had been suing vaccine manufacturers for injuries their children suffered at the hands of vaccines. Threatening to discontinue vaccine production, the vaccine manufacturers asked for government assurances that their products would go forward unhindered. The 1986 law took all liability away from the manufacturers of vaccines, making it impossible to sue the industry. The same law stipulated that every two years the Department of Health and Human Services (HHS) would submit a report to Congress on the state of vaccine safety. It was during this time that the numbers and doses of vaccines began a dramatic increase.

In 2017 Robert F. Kennedy Jr. and Del Bigtree of the Informed Consent Action Network (ICAN) filed a suit before the U.S. Federal Court for the Southern District of New York. On July 27, 2018, HHS admitted the following before the court:

The [Department]’s searches for records did not locate any records responsive to your request. Department of Health and Human Services (HHS) Immediate Office of the Secretary (IOS) conducted a thorough search of its document tracking systems. The department also conducted a comprehensive review of all relevant indexes of HHS secretarial correspondence records maintained at Federal record centers that remain in the custody of HHS. These searches did not locate records responsive to your request, or indications that records responsive to your request and in the custody of HHS are located at Federal record centers.

Today in the United States, political, medical, and mass media leadership, infused by the interests of vaccine manufacturers, are currently engaged in a massive campaign to silence dialogue, ban books and websites, avoid debates, and impose that vaccines become mandatory for all with no respect to informed consent, religious beliefs, medical conditions, or personal conscience. Writing on a recent measles outbreak in Rockland County, New York, Celeste McGovern remarks,

People, like those in Rockland County, don’t avoid vaccines because they are misled by “fake” news and Facebook – but because of the real stories of corporate greed and political cover-up and vaccine-injured children that are shared on those platforms. The data bears them out. There are millions of them.

How is it possible that censorship becomes a principal upon which public policy and social interaction are defined in a democracy? Will the violation of the right to informed consent become the new paradigm applied to air travel, medications, vaccination, food and more?

The very thought that censorship would become an instrument of intimidation, humiliation, a threat, and a practice violating human rights, should make anyone shiver. But maybe more importantly, the unbridled and crass censorship we are witnessing today on the topic of mandatory vaccination, its effectiveness and safety, should leave us asking: How is it possible that censorship becomes a principal upon which public policy and social interaction are defined in a democracy? Will the violation of the right to informed consent become the new paradigm applied to air travel, medications, vaccination, food, and more?

Personally, and professionally, I see nothing edifying and positive coming from the censorship of those that question. Boeing has explaining to do, as does the FAA. Furthermore, Johnson & JohnsonPurdueCVS and the FDA, owe the people an explanation. Likewise, the HHS, CDC, and pharma owe the people many explanations about the safety of vaccines.


Sign up for free news and updates from Robert F. Kennedy, Jr. and the Children’s Health Defense. CHD is planning many strategies, including legal, in an effort to defend the health of our children and obtain justice for those already injured. Your support is essential to CHD’s successful mission.

Help Support Collective Evolution

The demand for Collective Evolution's content is bigger than ever, except ad agencies and social media keep cutting our revenues. This is making it hard for us to continue.

In order to stay truly independent, we need your help. We are not going to put up paywalls on this website, as we want to get our info out far and wide. For as little as $3 a month, you can help keep CE alive!

SUPPORT CE HERE!

cards

Continue Reading
advertisement - learn more
advertisement - learn more

Video

Pod